TD Cowen analyst Joseph Thome has maintained their bullish stance on RAPP stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Thome has given his Buy rating due to a combination of factors, primarily centered around the promising results of Rapport Therapeutics, Inc.’s RAP-219 in its Phase II trial for focal epilepsy. The trial exceeded expectations with a significant reduction in clinical seizures and a strong tolerability profile, indicating a high potential for success in future trials. The positive reception from key opinion leaders and the novel trial design further bolster confidence in the drug’s efficacy.
Additionally, Rapport Therapeutics is well-positioned financially, with a substantial cash reserve that supports the advancement of RAP-219 into Phase III trials. The company’s strategic plans to engage with the FDA and initiate pivotal programs demonstrate a clear path forward. Despite a lighter catalyst year in 2026, the derisked profile of RAP-219 and the large market potential in epilepsy underpin the Buy recommendation.
According to TipRanks, Thome is a 5-star analyst with an average return of 20.6% and a 56.00% success rate. Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, AnaptysBio, and PTC Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.